Bidirectional Interactions Between Immune Regulation and the Insulin-like Growth Factor Axis in Colorectal Cancer

Area of Science:

• Oncology
• Immunology
• Endocrinology

Background:

• Colorectal cancer (CRC) is a leading global malignancy with complex molecular features impacting diagnosis and treatment.
• The insulin-like growth factor (IGF) axis plays a critical role in cancer development and interacts with the immune system.
• Understanding IGF-immune crosstalk is crucial for developing novel therapeutic strategies for CRC.

Purpose of the Study:

• To review the intricate relationship between IGF signaling and immune regulation in colorectal cancer.
• To elucidate the mechanisms by which IGF signaling contributes to tumor immunosuppression.
• To explore the potential of IGF network components as biomarkers for CRC detection and therapeutic targets.

Main Methods:

• Systematic review of existing literature on IGF axis, immune cells, and CRC.
• Analysis of mechanistic pathways linking IGF signaling to immune evasion (e.g., M2 macrophages, regulatory T cells).
• Evaluation of IGFBP-2 and other biomarkers in CRC diagnostics and their association with molecular subtypes.

Main Results:

• IGF signaling promotes immune evasion by influencing tumor-associated macrophages, regulatory T cells, and myeloid-derived suppressor cells.
• IGF binding protein 2 (IGFBP-2) is identified as a key mediator linking IGF signaling to immune evasion via STAT3 pathways.
• IGF-immune crosstalk differs across CRC molecular subtypes, with microsatellite-stable tumors relying on IGF-I receptor for immune silencing.
• Local IGF production becomes more significant in advanced stages of CRC.

Conclusions:

• Bidirectional IGF-immune interactions create self-reinforcing circuits that dictate tumor immunogenicity and response to therapy.
• Multi-marker panels including IGFBP-2 show promise for early CRC detection, necessitating further clinical validation.
• Combined targeting of IGF signaling and immune checkpoint pathways may overcome resistance to immunotherapy in certain CRC cases.